Key facts
- It has raised $12.5M; the latest was Seed Round ($12.0M) in Feb 2025.
- Notable investors include Life Sciences BC, InBC Investment, Finchley Healthcare Ventures, Amplitude Ventures, InBC Investment Corp. (InBC) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Reverb Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Reverb Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reverb Therapeutics
Developer of a cytokine therapy designed for cancer treatment and promoting targeted immune activation while limiting toxicity. The company uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines, enabling cancer patients and the healthcare sector to redirect endogenous cytokines already in the body to cells of interest and treat cancer.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2023
- Employees
- 10
- Website
- reverbtx.com/
- Ownership
- Privately Held (backing)
Reverb Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reverb Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reverb Therapeutics in its N-PORT filings yet. We sweep new filings monthly.